tbuckley/cabot-search huggingface dataset:
Alpha‐gal is a possible target of IgE‐mediated reactivity to antivenom
Authors: J. Fischer, B. Eberlein, C. Hilger, F. Eyer, S. Eyerich, M. Ollert, T. Biedermann
Journal: Allergy (2016)

Abstract Background Antivenoms are mammalian immunoglobulins with the ability to neutralize snake venom components and to mitigate the progression of toxic effects. Immediate hypersensitivity to antivenoms often occurs during the first administration of these heterologous antibodies. A comparable clinical situation occurred after introduction of cetuximab, a chimeric mouse–human antibody, for cancer treatment. The carbohydrate epitope galactose‐alpha‐1,3‐galactose, located on the Fab region of cetuximab, was identified as the target responsible for IgE reactivity. Objective To investigate whether serum IgE antibodies directed to the α‐gal epitope are associated with hypersensitivity to equine antivenoms. Methods Antivenoms were screened for α‐gal epitopes via immunoblot and in comparison with cetuximab and pork kidney by IgE reactivity assays. Basophil activation tests were used to investigate reactivity to antivenoms in samples from 20 patients with specific IgE antibodies to α‐gal and 10 controls. Additional IgE detection, IgE inhibition, Immuno CAP inhibition, and skin prick tests were performed using samples from selected patients. Results Both antivenoms and cetuximab induced positive skin prick test results in patients with sIgE to α‐gal. Alpha‐gal epitopes were detected by immunoblotting on antivenoms. Measurements of IgE reactivity and Immuno CAP inhibition indicated that the antivenoms contained lower α‐gal contents than cetuximab. Deglycosylation assays and IgE inhibition tests confirmed that IgE‐mediated reactivity to antivenom is associated with α‐gal. Antivenoms, pork kidney, and cetuximab activated basophils from patients with IgE to α‐gal. Conclusion Alpha‐gal is a potential target of IgE‐mediated reactivity to equine antivenom and a possible cause of the high incidence of hypersensitivity reactions during the first application of equine antivenom.
Identification of Novel Mutations in Dilated Cardiomyopathy Using the Haplotype Sharing Test
Authors: Paul A. van der Zwaag, Jan D. Jongbloed, Frans Gerbens, Ludolf G. Boven, Robert M. Hofstra, Gerard J. te Meerman, Maarten P. van den Berg, J. P. van Tintelen
Journal: Circulation (2009)
The Use of Low-Dose Alemtuzumab as Single Agent in the Treatment of Complication in Advanced Chronic Lymphocytic Leukaemia
Authors: Luca Laurenti, Michela Tarnani, Idanna Innocenti, Silvia De Matteis, Simona Sica, Federica Sorà, Patrizia Chiusolo, Dimitar Efremov, Sara Marietti, Giuseppe Leone
Journal: Blood (2008)
Cutaneous Lupus — “The Pimple That Never Went Away”
Authors: Vanessa Ocampo, Shariq Haider
Journal: New England Journal of Medicine (2016)

A 28-year-old woman presented with an erythematous rash on the nose and nasal area that appeared after she had manipulated a painful vesicular lesion. Cloxacillin therapy had a slight benefit followed by a worsening induration that prompted treatment with IV antibiotics, which had no effect.
Development of Prothrombinase Induced Clotting Time (Pefakit ®, PiCT) Assay and its Validation in the Monitoring of Anti-Xa and Anti-FIIa Drugs.
Authors: Debra A. Hoppensteadt, Josephine Cunanan, Jeanine M. Walenga, Jawed Fareed
Journal: Blood (2004)
Abstract IA24: Forcing through tumor metastasis: Regulation of epithelial-mesenchymal plasticity by matrix stiffness
Authors: Jing Yang
Journal: Cancer Research (2016)

Abstract In cancer, the presence of dense clusters of collagen fibrils indicates increased matrix stiffness and correlates with poor survival. Previous studies have identified a functional role for matrix stiffness in driving tumor progression, but it is unclear how mechanical inputs are transduced into transcriptional outputs to drive tumor metastasis. To investigate mechanisms of tumor cell mechanotransduction, we utilized a 3D Matrigel culture of murine (Eph4Ras) or human (MCF10A, MCF10DCIS, Bt-549) mammary epithelial cells coupled with a polyacrylamide hydrogel base with calibrated elastic moduli ranging between ~150Pa of normal mammary gland and ~5700Pa of breast tumor tissues. This approach allows for the interrogation of the effects of changes in matrix stiffness independent of other biochemical variables in extracellular matrix (ECM). Using this system, we show that increasing matrix stiffness induced morphological changes resembling the Epithelial-Mesenchymal Transition (EMT) program. Therefore, we hypothesized that increasing matrix stiffness could directly signal through EMT-inducing transcription factors to induce EMT and promote invasion. Using a combination of bioengineering, cell biollogy, proteomic, imaging, and murine tumor modeling approaches, we found that the EMT-inducing transcription factor TWIST1 is an essential mechanomediator that promotes EMT in response to increasing matrix stiffness. Loss of Twist1 prevents matrix stiffness-induced EMT and tumor cell invasion. TGF-beta signaling, a major EMT-inducing biochemical signal, acts synergistically with increasing matrix stiffness, the mechanical cure to induce a complete EMT program in a Twist1-dependent manner. At the compliant matrix stiffness, TWIST1 is sequestered in the cytoplasm by its cytoplasmic binding partner G3BP2, thus preventing TWIST1 from accessing DNA to drive EMT. High matrix stiffness promotes nuclear translocation of TWIST1 by releasing TWIST1 from G3BP2. Loss of G3BP2 leads to constitutive TWIST1 nuclear localization and synergizes with increasing matrix stiffness to induce EMT and invasion in a Twist1-dependent manner. In MCF10DCIS breast tumor xenografts, loss of G3BP2 promotes local invasion and distant metastasis in the lung. In human stage-3 breast tumors, collagen fiber alignment, a marker of increasing matrix stiffness, and reduced expression of G3BP2 together predict poor survival. Together, our findings reveal a TWIST1-G3BP2 mechanotransduction pathway that responds to biomechanical signals from the tumor microenvironment to drive EMT, invasion and metastasis. Citation Format: Jing Yang. Forcing through tumor metastasis: Regulation of epithelial-mesenchymal plasticity by matrix stiffness. [abstract]. In: Proceedings of the AACR Special Conference: Function of Tumor Microenvironment in Cancer Progression; 2016 Jan 7–10; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2016;76(15 Suppl):Abstract nr IA24.
Dyadic exercise to reduce depression and associated inflammatory cytokines among lesbian, gay, and heterosexual cancer survivors.
Authors: Charles Stewart Kamen, Luke Joseph Peppone, Gary R. Morrow, Karen Michelle Mustian, Kathi Heffner, Michelle Christine Janelsins
Journal: Journal of Clinical Oncology (2016)

10069 Background: Our previous research shows that lesbian/gay (LG) cancer survivors experience high rates of depression and that standardized aerobic and resistance exercise (EXCAP, Exercise for Cancer Patients) is efficacious in improving depression and inflammation associated with depression in heterosexual survivors. We have now conducted the first, to our knowledge, cancer control trial testing two exercise interventions to reduce depression and inflammation in both LG and heterosexual survivors and their caregivers (CGs). Methods: In this Phase I/II RCT, 42 LG and heterosexual survivors and their CGs were randomized as dyads to: Arm 1) dyadic exercise, involving both survivor and CG; or Arm 2) survivor-only EXCAP. Depression symptoms (from the CES-D) and cytokines (IFN-γ, IL-6, IL-8, IL-10) were measured at baseline and post-intervention (6 wks later). We used t-tests to assess baseline disparities, ANCOVA to assess the effect of dyadic vs. survivor-only exercise on depression and inflammation, and Pearson correlations to assess mechanistic associations between changes in depression and inflammation. Results: At baseline, LG survivors reported higher depression (t = -2.23, p = 0.04), and had higher IL-6 (t = -2.53, p = 0.02) and IL-8 (t = 2.37, p = 0.03) than heterosexuals. Among both LG and heterosexual survivors, dyadic exercisesignificantly improved depression relative to survivor-only exercise (M = -5.17, vs. M = 2.43; p = 0.02). Decreases in depression were associated with decreases in IL-6 (r= 0.40, p = .03) and IL-8 (r= 0.39, p = 0.04); in analyses by sexuality group and intervention, these associations were significant only among LG survivors in the dyadic exercise condition. Conclusions: This study replicates previous research showing disparities between LG and heterosexual survivors and offers preliminary support for the use of exercise in general and dyadic exercise in specificfor reducing depression among LG and heterosexual survivors. It suggests a biological mechanism by which this improvement occurs, namely by reducing systemic inflammation. Confirmatory research is needed to replicate these findings in larger samples of cancer survivors. Clinical trial information: NCT01883635.
Abstract C07: Cancer-associated fibroblasts: Co-migrating from primary to metastatic tumor sites
Authors: Nour Ershaid, Raz Yael, Neta Erez
Journal: Cancer Research (2016)

Abstract Breast tumors are characterized by an extensive desmoplastic stroma, abundantly populated by fibroblasts. Cancer-associated fibroblasts (CAFs) are the most abundant cell type in tumor stroma. CAFs are an essential component of the tumor microenvironment involved in many processes that promote tumor progression, including growth promoting, pro-angiogenic and pro-inflammatory signaling. In addition, CAFs were shown to support cancer cell invasion and metastasis via their extracellular matrix remodeling capacities. However, a direct active participation of CAFs in supporting the dissemination of cancer cells to secondary organs and supporting metastatic colonization is still largely obscure. We show that fibroblasts from mammary tumors are capable of co-migrating with disseminated tumor cells to the lungs and are incorporated into ensuing pulmonary metastases. We utilized novel multi-transgenic mouse models of spontaneous breast carcinoma and lung metastasis (MMTV-PyMT) combined with transgenic mice in which fibroblasts are genetically labeled with fluorescent reporter genes, thus allowing their unbiased tracking and isolation during tumor progression and metastasis. By orthotopic transplantations of fluorescently labeled tumors we were able to detect CAFs derived from primary tumors in lung metastases. We plan to characterize the functional role of co-migrating CAFs by analyzing the transcriptional changes that migrating CAFs undergo in the process. We will seek to uncover specific molecular pathways which contribute to the reciprocal interactions between migrating CAFs and cancer cells which serve to promote and enhance the metastatic process. In summary, we were able to uncover a novel role for mammary CAFs in which they co-migrate with cancer cells from the primary tumor to metastatic sites in the lungs. Citation Format: Nour Ershaid, Raz Yael, Neta Erez. Cancer-associated fibroblasts: Co-migrating from primary to metastatic tumor sites. [abstract]. In: Proceedings of the AACR Special Conference: Function of Tumor Microenvironment in Cancer Progression; 2016 Jan 7–10; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2016;76(15 Suppl):Abstract nr C07.
HIF1-Alpha and MYC Transcription Factor Signatures in B-Cell Acute Lymphoblastic Leukemia Are Associated with Positive Minimal Residual Disease Status: Therapeutic Implications
Authors: Tomasz Sewastianik, Patryk Gorniak, Przemyslaw Kiliszek, Anna Polak, Emilia Bialopiotrowicz, Ewa Jablonska, Maciej Szydlowski, Ewa Lech-Maranda, Katarzyna Borg, Hanna Makuch-Lasica, Adam Zabek, Piotr Mlynarz, Tomasz Stoklosa, Sebastian Giebel, Krzysztof Warzocha, Przemyslaw Juszczynski
Journal: Blood (2015)
Cost-effectiveness of biomarker-directed bevacizumab for first-line therapy of persons with metastatic colorectal cancer.
Authors: Kristin Berry, Mark Eliot Bensink, Zahra Musa, Veena Shankaran, Edward H. Lin, Uri Ladabaum, Carolyn Bodnar, Michael Birt, Scott David Ramsey
Journal: Journal of Clinical Oncology (2012)

6077 Background: When added to first-line chemotherapy for metastatic colorectal cancer, bevacizumab provides a moderate survival increase, but is associated with significant adverse events and high cost. As only a minority of patients respond to antiangiogenic therapy, a diagnostic that identifies potential responders ex ante could potentially change the benefit to risk profile of bevacizumab and likely improve cost-effectiveness. Since efforts to identify a predictive test have so far been unsuccessful, a novel strategy may be to measure tumor response after bevacizumab treatment initiation using an in vivo biomarker test to guide decisions on whether patients should continue treatment. The objective is to estimate the cost-effectiveness of biomarker-directed use of bevacizumab in first-line treatment of metastatic colorectal cancer compared to standard care. Methods: The analysis takes the perspective of the US healthcare system. A decision model was built to estimate the incremental effect of adding bevacizumab to IFL, FOLFIRI, 5FU/LV and FOLOFOX/XELOX regimens. Survival data, estimated through a meta-analysis of four clinical trials, combined with utilities from the literature were used to calculate quality-adjusted life years (QALYs). Costs were based on Medicare reimbursement and expert opinion. Assumed performance characteristics of the biomarker technology (sensitivity, specificity – provided by our industry partner) were 75% and 95% 10 days after commencement of bevacizumab. Results: The biomarker-directed bevacizumab strategy dominated usual care, providing both an average per patient gain of 0.015 QALYs and a cost-savings of $21,038. The cost-effectiveness of the biomarker technology was most influenced by the cost of the test and colorectal cancer utilities. Variations in biomarker specificity and sensitivity changed the magnitude of cost-savings and benefit gain but did not change the overall result of dominance. Conclusions: Modeling predicts that a validated marker which could identify responders to bevacizumab will save money and improve quality-adjusted life years. The results support additional investment in identifying such a diagnostic.
Do You Dare to Dharma?
Authors: Alexandra E. Hedberg
Journal: JAMA (2016)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
За матеріалами IV наукової сесії Інституту гастроентерології НАМН України «Новітні технології в теоретичній та клінічній гастроентерології»
Authors: I.Yu. Skyrda, O.P. Halenko
Journal: GASTROENTEROLOGY (2016)

У статті наведені матеріали IV наукової сесії Інституту гастроентерології НАМН України «Новітні технології в теоретичній та клінічній гастроентерології», яка проводилася 16–17 червня 2016 р. у м. Дніпрі Державною установою «Інститут гастроентерології НАМН України» у діловому центрі «Менора».Науковий керівник конференції — Юрій Миронович Степанов, доктор медичних наук, професор, заслужений лікар України, директор ДУ «Інститут гастроентерології НАМН України», завідувач кафедри гастроентерології та терапії ФПО ДЗ «Дніпропетровська медична академія», голова спілки «Асоціація з вивчення та лікування хвороб органів травлення в Україні».
A Phase I/II Study Of Cytarabine Or Azacitidine In Combination With Tosedostat In Older Patients With AML Or High-Risk MDS
Authors: Courtney D. DiNardo, Hagop M Kantarjian, Farhad Ravandi, Marina Konopleva, Tapan M. Kadia, Gautam Borthakur, Naval G. Daver, Menda Durand, Silvia Rivera, Alfonso Quintás-Cardama, Guillermo Garcia-Manero, Jorge E. Cortes
Journal: Blood (2013)
Osimertinib for pretreated EGFR Thr790Met-positive advanced non-small-cell lung cancer (AURA2): a multicentre, open-label, single-arm, phase 2 study
Authors: Glenwood Goss, Chun-Ming Tsai, Frances A Shepherd, Lyudmila Bazhenova, Jong Seok Lee, Gee-Chen Chang, Lucio Crino, Miyako Satouchi, Quincy Chu, Toyoaki Hida, Ji-Youn Han, Oscar Juan, Frank Dunphy, Makoto Nishio, Jin-Hyoung Kang, Margarita Majem, Helen Mann, Mireille Cantarini, Serban Ghiorghiu, Tetsuya Mitsudomi
Journal: The Lancet Oncology (2016)
Oncoplastic reduction mammoplasty for breast cancer in woman with macromastia: Oncological long-term outcomes.
Authors: Mustafa Emiroglu, Semra Salimoglu, Cem Karaali, Ismail Sert, Osman Gungor, Fatma Sert, Cengiz Aydin
Journal: Journal of Clinical Oncology (2015)

e12057 Background: Despite the increase in studies of ORM, data showing long-term oncological results, aesthetic and patient satisfaction for ORM in patients with macromastia is still limited. Therefore, this study aimsto evaluate the long-term results of tumorectomy and concomitant bilateral oncoplastic reduction mammoplasty (ORM) for early-stage breast cancer patients with macromastia, in terms of localdisease control, cosmesis and patient satisfaction. Methods: The prospective observational data of 82 patients with macromastia undergoing ORM for breast cancer between 1996 and 2011 were examined and evaluated with regard to oncological results, aesthetic results and patient satisfaction. Results: The median age was 50. The median follow up was 120 months (range 28-212). The median breast volume was 1402 cm3 and the median weight of excised breast material was 679g. The median surgical margin was 16 mm. The 10 year overall survival rate was 82.2% and the disease free survival rate was 73.2%. A good or excellent evaluation of the cosmetic outcome was as follows: self-evaluation: 84.1% at early-stage, 80.3% at later stage; panel evaluation: 75.4% at late stage. The median patient satisfaction rate was: early stage 9.1 and late stage 8.8. Conclusions: From the standpoint of local disease control and long-term observation, ORM can be considered a very safe and acceptable treatment for early-stage breast cancer in women with macromastia. Cosmetic results of ORM were also acceptable in both short and long term. Patients were extremely pleased to have both the breast cancer and the macromastia symptoms treated in a single session.
GW26-e0377 The Study of Chronic Intermittent Hypoxia Caused by Obstructive Sleep Apnea to the Rat Myocardial Cell Apoptosis and Myocardial Fibrosis
Authors: Fuchao Yu, Dan Li, Zhouzhou Lu, Xiaohui Zhang, Jiayi Tong
Journal: Journal of the American College of Cardiology (2015)
The Emerging Importance of Non-HLA Autoantibodies in Kidney Transplant Complications
Authors: Héloise Cardinal, Mélanie Dieudé, Marie-Josée Hébert
Journal: Journal of the American Society of Nephrology (2016)

Antibodies that are specific to organ donor HLA have been involved in the majority of cases of antibody-mediated rejection in solid organ transplant recipients. However, recent data show that production of non-HLA autoantibodies can occur before transplant in the form of natural autoantibodies. In contrast to HLAs, which are constitutively expressed on the cell surface of the allograft endothelium, autoantigens are usually cryptic. Tissue damage associated with ischemia-reperfusion, vascular injury, and/or rejection creates permissive conditions for the expression of cryptic autoantigens, allowing these autoantibodies to bind antigenic targets and further enhance vascular inflammation and renal dysfunction. Antiperlecan/LG3 antibodies and antiangiotensin II type 1 receptor antibodies have been found before transplant in patients with de novo transplants and portend negative long–term outcome in patients with renal transplants. Here, we review mounting evidence suggesting an important role for autoantibodies to cryptic antigens as novel accelerators of kidney dysfunction and acute or chronic allograft rejection.
Vibrio parahaemolyticus Flagellin Stimulates the Maturation of Human Monocyte-Derived Dendritic Cells and Elicits Th1-Type Immune Response.
Authors: Hyun-Kyu Kang, Myong-Suk Park, Shee-Eun Lee, Joon-Haeng Rhee, Jung-Sun Park, Thanh-Nhan Nguyen, Xiao-Wei Zhu, Duck Cho, Jong-Hee Nam, Young-Jin Kim, Hyeoung Joon Kim, Je-Jung Lee
Journal: Blood (2005)
Zoonia Nazir Chaudhry
Authors: Simon Heyland, Jelena Jankovic
Journal: BMJ (2016)

Zoonia Nazir Chaudhry was born in Lahore, Pakistan. She graduated MBBS from Fatima Jinnah Medical College in Lahore and started her postgraduate training there, gaining her fellowship of the College of Physicians and Surgeons, Pakistan (FCPS) in psychiatry. Zoonia started working as a trainee psychiatrist in the UK in 2001. She worked in Shrewsbury …
University of Pennsylvania.
Journal: JAMA (1884)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal